Mishima Gerhart
Conseiller Juridique Général chez PLIANT THERAPEUTICS, INC.
Profil
Mishima Gerhart is currently the Chief Regulatory Officer at Pliant Therapeutics, Inc. Prior to this, Mishima held positions as the Head-Regulatory Affairs at Genzyme Corp.
from 2014 to 2016, and as the Head-Global Regulatory Affairs at Sanofi from 2016 to 2020.
Mishima also served as the Chief Regulatory Officer & Head-Quality at Taysha Gene Therapies, Inc. Mishima's education includes an undergraduate degree from Kutztown University of Pennsylvania and a graduate degree from Temple University (Pennsylvania).
Postes actifs de Mishima Gerhart
| Sociétés | Poste | Début |
|---|---|---|
| PLIANT THERAPEUTICS, INC. | Conseiller Juridique Général | 16/10/2023 |
Anciens postes connus de Mishima Gerhart
| Sociétés | Poste | Fin |
|---|---|---|
| SANOFI | Conseiller Juridique Général | 01/06/2020 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Conseiller Juridique Général | 01/01/2016 |
| TAYSHA GENE THERAPIES, INC. | Conseiller Juridique Général | - |
Formation de Mishima Gerhart
| Kutztown University of Pennsylvania | Undergraduate Degree |
| Temple University (Pennsylvania) | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| SANOFI | Health Technology |
| PLIANT THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
